Literature DB >> 30110044

Adropin and Irisin in Patients with Cardiac Cachexia.

Alfredo José Mansur1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30110044      PMCID: PMC6078362          DOI: 10.5935/abc.20180109

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


× No keyword cloud information.
Cardiological clinical practice involves the care of patients with heart failure who lose weight, which not rarely culminates in cardiac cachexia. The differential diagnosis with other consumptive disorders can lead to an extensive diagnostic investigation. That has been a theme of interest in the medical literature for decades,[1] and its importance remains recognized over time.[2-7] Physicians with decades of experience in cardiological clinical practice have noticed that individuals with heart failure due to heart valvular disease gain weight after well-succeeded surgical interventions that reverse heart failure. In other words, heart failure reversion also manifests as weight gain. A recent outpatient clinical observation [Correia GF & Lima NNC, unpublished data] of 36 patients for months has found body weight variation with the current pharmacological treatment for heart failure including betablockers (Figure 1).
Figure 1

Body weight variation in 2 observations.

Body weight variation in 2 observations. Different metabolic mechanisms can mediate that clinical manifestation.[8,9] In this issue of the Arquivos Brasileiros de Cardiologia, Kalkan et al.[10] have added to the studies in the area the results of the research on two proteins that act on the mechanisms of energetic homeostasis – adropin[11] and irisin.[12] Those authors have found that the concentration of those proteins differed in 44 patients with cachexia (body mass index 19.9; standard deviation 1.12) as compared to that of 42 patients without cachexia (body mass index 29.2; standard deviation 4.25). On multivariate logistic regression, adropin remained associated with cachexia, despite the low hazard ratio. Some limitations of the study by Kalkan et al.[10] were the lack of information about the etiology of heart failure, the small sample size and the lack of log-term follow-up data. Therefore, the results presented, although initial and exploratory, are important, and further studies should be conducted to elucidate the metabolic mechanisms of weight loss in patients with heart failure.
  11 in total

Review 1.  THE PATHOGENESIS OF CARDIAC CACHEXIA.

Authors:  J G PITTMAN; P COHEN
Journal:  N Engl J Med       Date:  1964-08-20       Impact factor: 91.245

2.  [Nutritional repercussion in advanced heart failure and its value in prognostic assessment].

Authors:  Luís Guilherme Veloso; Mucio Tavares de Oliveira; Robson Tadeu Munhoz; Paulo Cesar Morgado; José Antonio Franchini Ramires; Antonio Carlos Pereira Barretto
Journal:  Arq Bras Cardiol       Date:  2005-06-28       Impact factor: 2.000

3.  [Score for nutritional status evaluation: the role played in the prognostic stratification of dilated cardiomyopathy and advanced heart failure patients].

Authors:  Luiz Guilherme Veloso; Antonio Carlos Pereira-Barretto; Mucio Tavares de Oliveira; Robson Tadeu Munhoz; Paulo César Morgado; José Antonio Franchini Ramires
Journal:  Arq Bras Cardiol       Date:  2006-08       Impact factor: 2.000

Review 4.  Treatment of cachexia: An overview of recent developments.

Authors:  Stephan von Haehling; Stefan D Anker
Journal:  Int J Cardiol       Date:  2014-10-16       Impact factor: 4.164

5.  Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.

Authors:  Stefan D Anker; Abdissa Negassa; Andrew J S Coats; Rizwan Afzal; Philip A Poole-Wilson; Jay N Cohn; Salim Yusuf
Journal:  Lancet       Date:  2003-03-29       Impact factor: 79.321

6.  Adropin is a novel regulator of endothelial function.

Authors:  Fina Lovren; Yi Pan; Adrian Quan; Krishna K Singh; Praphulla C Shukla; Milan Gupta; Mohammed Al-Omran; Hwee Teoh; Subodh Verma
Journal:  Circulation       Date:  2010-09-14       Impact factor: 29.690

7.  [Malnutrition in dilated cardiomyopathy. Correlation with echocardiographic indices of left ventricular function].

Authors:  L G Velloso; L F Csengeri; R R Alonso; C M Ciscato; A C Barreto; G Bellotti; F Pileggi
Journal:  Arq Bras Cardiol       Date:  1992-03       Impact factor: 2.000

Review 8.  Cardiac cachexia: a systematic overview.

Authors:  Stephan von Haehling; Mitja Lainscak; Jochen Springer; Stefan D Anker
Journal:  Pharmacol Ther       Date:  2008-11-14       Impact factor: 12.310

9.  Cardiac Cachexia - A Window to the Wasting DisordersCardiac cachexia: perspectives for prevention and treatmentSkeletal muscle aging: influence of oxidative stress and physical exerciseCancer-induced muscle wasting: latest findings in prevention and treatmentCancer-induced cardiac cachexia: pathogenesis and impact of physical activity (Review)Muscle wasting and cachexia in heart failure: mechanisms and therapiesEffects of growth hormone on cardiac remodeling and soleus muscle in rats with aortic stenosis-induced heart failure.

Authors:  Andrew J Stewart Coats
Journal:  Arq Bras Cardiol       Date:  2018-01       Impact factor: 2.000

Review 10.  The Role of Physical Exercise to Improve the Browning of White Adipose Tissue via POMC Neurons.

Authors:  Kellen C da Cruz Rodrigues; Rodrigo M Pereira; Thaís D P de Campos; Rodrigo F de Moura; Adelino S R da Silva; Dennys E Cintra; Eduardo R Ropelle; José R Pauli; Michel B de Araújo; Leandro P de Moura
Journal:  Front Cell Neurosci       Date:  2018-03-28       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.